LSTM Group

LSTM-Group.com

We provide as PMP Innovation- and New Business Development Experts (NBDE) Future Business in Technology Scouting, Research Advanced Functional Materials, Functional Silane Hybrid Polymer Resin and Latent Nano Technology, PMP/PMO Professional Project Management, R&D-Service and Sustainable Technology to support your excellent Future Innovation Business Demands in

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

UPCOMING XTALKS WEBINAR WILL DISCUSS PHARMACEUTICAL COMMERCIAL LAUNCH READINESS WITH SECRETS TO DE-RISK AND ACCELERATE SUCCESS

XTALKS | July 18, 2020

news image

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...

Read More

TELIX PHARMACEUTICALS ENTERS STRATEGIC COLLABORATION WITH VARIAN MEDICAL SYSTEMS FOR ADVANCED PROSTATE IMAGING

Telix Pharmaceuticals Limited | September 07, 2020

news image

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission to...

Read More

Research

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

news image

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More

Business Insights

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More
news image

UPCOMING XTALKS WEBINAR WILL DISCUSS PHARMACEUTICAL COMMERCIAL LAUNCH READINESS WITH SECRETS TO DE-RISK AND ACCELERATE SUCCESS

XTALKS | July 18, 2020

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...

Read More
news image

TELIX PHARMACEUTICALS ENTERS STRATEGIC COLLABORATION WITH VARIAN MEDICAL SYSTEMS FOR ADVANCED PROSTATE IMAGING

Telix Pharmaceuticals Limited | September 07, 2020

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission to...

Read More
news image

Research

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More
news image

Business Insights

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us